{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:14:03Z","timestamp":1793394843637,"version":"4.5.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The global measles vaccination program has been extraordinarily successful in reducing measles-related disease and deaths worldwide. Eradication of measles is feasible because of several key attributes, including humans as the only reservoir for the virus, broad access to diagnostic tools that can rapidly detect measles-infectious persons, and availability of highly safe and effective measles-containing vaccines (MCVs). All 6 World Health Organization (WHO) regions have established measles elimination goals. Globally, during 2000\u20132018, measles incidence decreased by 66% (from 145 to 49 cases per million population) and deaths decreased by 73% (from 535 600 to 142 300), drastically reducing global disease burden. Routine immunization with MCV has been the cornerstone for the control and prevention of measles. Two doses of MCV are 97% effective in preventing measles, qualifying MCV as one of the most effective vaccines ever developed. Mild adverse events occur in &amp;lt;20% of recipients and serious adverse events are extremely rare. The economic benefits of measles vaccination are highlighted by an overall return on investment of 58 times the cost of the vaccine, supply chains, and vaccination. Because measles is one of the most contagious human diseases, maintenance of high (\u226595%) 2-dose MCV coverage is crucial for controlling the spread of measles and successfully reaching measles elimination; however, the plateauing of global MCV coverage for nearly a decade and the global measles resurgence during 2018\u20132019 demonstrate that much work remains. Global commitments to increase community access to and demand for immunizations, strengthen national and regional partnerships for building public health infrastructure, and implement innovations that can overcome access barriers and enhance vaccine confidence, are essential to achieve a world free of measles.<\/jats:p>","DOI":"10.1093\/infdis\/jiaa793","type":"journal-article","created":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T23:11:38Z","timestamp":1609197098000},"page":"S420-S428","source":"Crossref","is-referenced-by-count":117,"title":["Measles in the 21st Century: Progress Toward Achieving and Sustaining Elimination"],"prefix":"10.1093","volume":"224","author":[{"given":"Paul A","family":"Gasta\u00f1aduy","sequence":"first","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L","family":"Goodson","sequence":"additional","affiliation":[{"name":"Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Panagiotakopoulos","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A","family":"Rota","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walt A","family":"Orenstein","sequence":"additional","affiliation":[{"name":"Emory University and the Emory Vaccine Center, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"2021093008012247100_CIT0003","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/cid\/cix307","article-title":"Subacute sclerosing panencephalitis","volume":"65","author":"Rota","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021093008012247100_CIT0013","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/infdis\/jiy701","article-title":"International importations of measles virus into the United States during the post-elimination era, 20012016","volume":"219","author":"Lee","year":"2019","journal-title":"J Infect Dis"},{"key":"2021093008012247100_CIT0015","first-page":"1","article-title":"Meeting of the strategic advisory group of experts on immunization, November 2010\u2014summary, conclusions and recommendations","volume":"86","author":"World Health Organization","year":"2011","journal-title":"Wkly Epidemiol Rec"},{"key":"2021093008012247100_CIT0026","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/infdis\/162.5.1036","article-title":"Measles antibody: reevaluation of protective titers","volume":"162","author":"Chen","year":"1990","journal-title":"J Infect Dis"},{"key":"2021093008012247100_CIT0028","first-page":"1","article-title":"Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"McLean","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"2021093008012247100_CIT0034","volume-title":"Adverse effects of vaccines: evidence and causality","author":"Committee to Review Adverse Effects of Vaccines, Institute of Medicine","year":"2011"},{"key":"2021093008012247100_CIT0052","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/infdis\/jiz159","article-title":"Early measles vaccination during an outbreak in the Netherlands: short-term and long-term decreases in antibody responses among children vaccinated before 12 months of age","volume":"220","author":"Brinkman","year":"2019","journal-title":"J Infect Dis"},{"key":"2021093008012247100_CIT0055","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.15585\/mmwr.mm6945a6","article-title":"Progress toward regional measles elimination\u2013worldwide, 2000\u20132019","volume":"69","author":"Patel","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021093008012247100_CIT0056","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.15585\/mmwr.mm6740a4","article-title":"Vaccination coverage among children aged 19\u201335 months\u2014United States, 2017","volume":"67","author":"Hill","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021093008012247100_CIT0060","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1377\/hlthaff.2015.1086","article-title":"Return on investment from childhood immunization in low- and middle-income countries, 2011\u201320","volume":"35","author":"Ozawa","year":"2016","journal-title":"Health Aff"},{"key":"2021093008012247100_CIT0066","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/cid\/ciaa070","article-title":"A review of measles outbreak cost estimates from the US in the post-elimination era (2004\u20132017): estimates by perspective and cost type","volume":"71","author":"Pike","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021093008012247100_CIT0074","doi-asserted-by":"crossref","first-page":"893","DOI":"10.15585\/mmwr.mm6840e2","article-title":"National update on measles cases and outbreaks\u2014United States, January 1-October 1, 2019","volume":"68","author":"Patel","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021093008012247100_CIT0078","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.vaccine.2017.09.026","article-title":"Measles and Rubella Global Strategic Plan 2012\u20132020 midterm review","volume":"36","author":"Orenstein","year":"2018","journal-title":"Vaccine"},{"key":"2021093008012247100_CIT0087","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1017\/S0950268815000540","article-title":"Investigation of a measles outbreak in Zimbabwe, 2010: potential of a point of care test to replace laboratory confirmation of suspected cases","volume":"143","author":"Shonhai","year":"2015","journal-title":"Epidemiol Infect"},{"key":"2021093008012247100_CIT0093","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/infdis\/jiy139","article-title":"A microneedle patch for measles and rubella vaccination is immunogenic and protective in infant rhesus macaques","volume":"218","author":"Joyce","year":"2018","journal-title":"J Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/224\/Supplement_4\/S420\/40481462\/jiaa793.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/224\/Supplement_4\/S420\/40481462\/jiaa793.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T04:11:17Z","timestamp":1632975077000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/224\/Supplement_4\/S420\/6378081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":15,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2021,9,30]]},"published-print":{"date-parts":[[2021,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa793","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,9,30]]}}}